source
- Four-Year Follow-Up Shows Flat Survival Curves with Frontline Checkpoint Inhibitors in dMMR Endometrial CancerData presented at the 2026 Society of Gynecologic Oncology meeting examined four-year outcomes for patients with dMMR endometrial cancer treated with frontline checkpoint inhibitors. The results s…
- Gene therapy leaders in Rome flag FDA regulatory shifts as key challengeGene therapy manufacturers gathered in Rome to discuss the sector’s outlook in Europe, with the U.S. Food and Drug Administration’s recent actions dominating conversation. Speakers highlighted rec…